commercial agreements. Other important risks and uncertainties
are detailed in the company's reports and other filings with the Securities
and Exchange Commission, including its most recent Quarterly Report on Form
10-Q. Actual results could differ materially from the forward-looking
statements contained in this press release. The company undertakes no
obligation to update forward-looking statements, whether as a result of new
information, future events or otherwise.
Stephan Herrera, 415-488-7699
sherrera@nektar.com
Jennifer Ruddock, 650-631-4954
jruddock@nektar.com
NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
Unaudited Unaudited
Three-Months Ended Six-Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenue:
Product sales and royalties $9,010 $49,302 $19,381 $122,321
Contract research 11,391 16,615 21,012 28,612
Total revenue 20,401 65,917 40,393 150,933
Operating costs and expenses:
Cost of goods sold 5,444 39,490 12,671 96,012
Idle Manufacturing Costs 1,487 - 6,821 -
Research and development 33,500 41,000 70,873 78,492
General and administrative 13,091 13,178 24,802 29,913
Amortization of other
intangible assets 237 237 473 473
Total operating costs and expenses 53,759 93,905 115,640 204,890
<
'/>"/>SOURCE Nektar Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer2.
Nektar Therapeutics Announces First Quarter 2008 Results3.
FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform4.
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results5.
Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets6.
Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City7.
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia8.
Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York9.
Nektar Therapeutics Announces Third Quarter 2007 Financial Results10.
Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets11.
InteKrin Therapeutics Announces $20 Million Series C Financing